Cover Image
市場調查報告書

普拉得威利症候群(PWS):開發中產品分析

Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 321896
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
普拉得威利症候群(PWS):開發中產品分析 Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2018
出版日期: 2018年01月31日 內容資訊: 英文 82 Pages
簡介

普拉得威利症候群(PWS)是出生時出現許多身體功能障礙,精神功能障礙,行動障礙的罕見遺傳性疾病。症狀有肌肉張力低落,性荷爾蒙低,持續性的飢餓感等。

本報告提供普拉得威利症候群(PWS)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

普拉得威利症候群(PWS)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的開發企業

  • Chong Kun Dang Pharmaceutical Corp.
  • Essentialis, Inc.
  • Ferring International Center S.A.
  • LG Life Sciences, Ltd.
  • P2D Bioscience
  • Pfizer Inc.
  • Rhythm Pharmaceuticals

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • beloranib
  • betahistine hydrochloride
  • diazoxide choline CR
  • FE-992097
  • NOX-B11
  • setmelanotide
  • somatropin SR

開發中產品的最新趨勢

產品開發的里程碑

  • 熱門新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10134IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2018, provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape.

Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in a number of physical, mental and behavioral problems. Symptoms include poor muscle tone, low levels of sex hormones and a constant feeling of hunger.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 2, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Prader-Willi Syndrome (PWS) - Overview
    • Prader-Willi Syndrome (PWS) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Prader-Willi Syndrome (PWS) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development
    • Chong Kun Dang Pharmaceutical Corp
    • Ferring International Center SA
    • Insys Therapeutics Inc
    • LG Chem Ltd
    • Millendo Therapeutics Inc
    • OptiNose US Inc
    • Saniona AB
    • Soleno Therapeutics Inc
    • Zafgen Inc
  • Prader-Willi Syndrome (PWS) - Drug Profiles
    • (metoprolol + tesofensine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZP-531 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • beloranib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carbetocin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-Tagatose - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diazoxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diazoxide choline CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GLWL-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HM-04 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KAL-671 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxytocin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxytocin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • setmelanotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate snRNP-N for Prader-Willi Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Glycogen Synthase for Prader Willi Syndrome and Glycogen Storage Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • somatropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZGN-1258 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Prader-Willi Syndrome (PWS) - Dormant Projects
  • Prader-Willi Syndrome (PWS) - Discontinued Products
  • Prader-Willi Syndrome (PWS) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 16, 2018: Saniona initiates Phase I study with new Tesomet tablet
      • Jan 08, 2018: Saniona reports top line results from the Tesomet Phase 2a interim study in Prader-Willi syndrome
      • Dec 26, 2017: FDA Grants INSYS Therapeutics 'Fast Track' Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome
      • Oct 26, 2017: Saniona AB: Saniona decides to perform interim analysis of Tesomet study in patients with Prader-Willi syndrome
      • Oct 12, 2017: Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome
      • Oct 11, 2017: Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome
      • Sep 25, 2017: Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome
      • Sep 15, 2017: Soleno Therapeutics Presents Updated Safety and Efficacy Data from Clinical Trial of DCCR for Treatment of Prader-Willi Syndrome
      • Sep 13, 2017: Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR in Treatment of Prader-Willi Syndrome
      • Jul 05, 2017: Soleno Therapeutics Announces Successful Completion of FDA Meeting for DCCR in Prader-Willi Syndrome
      • Apr 03, 2017: Saniona initiates Phase 2a study for Tesomet in Prader-Willi syndrome
      • Mar 20, 2017: Saniona expects to initiate the planed Phase 2a study for Tesomet in Prader-Willi syndrome in Q2 2017
      • Nov 07, 2016: Saniona Plans To Initiate Phase 2A Study In Prader-Willi In 2017
      • Jul 20, 2016: Kalytera Therapeutics Presents New Data Demonstrating KAL671 Ability to Prevent Bone Loss in a Prader-Willi Syndrome Animal Model
      • Jul 18, 2016: Alize Pharma to present results from AZP-531 Phase II trial in Prader-Willi syndrome at two upcoming scientific conferences
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Prader-Willi Syndrome (PWS) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
  • Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center SA, H1 2018
  • Prader-Willi Syndrome (PWS) - Pipeline by Insys Therapeutics Inc, H1 2018
  • Prader-Willi Syndrome (PWS) - Pipeline by LG Chem Ltd, H1 2018
  • Prader-Willi Syndrome (PWS) - Pipeline by Millendo Therapeutics Inc, H1 2018
  • Prader-Willi Syndrome (PWS) - Pipeline by OptiNose US Inc, H1 2018
  • Prader-Willi Syndrome (PWS) - Pipeline by Saniona AB, H1 2018
  • Prader-Willi Syndrome (PWS) - Pipeline by Soleno Therapeutics Inc, H1 2018
  • Prader-Willi Syndrome (PWS) - Pipeline by Zafgen Inc, H1 2018
  • Prader-Willi Syndrome (PWS) - Dormant Projects, H1 2018
  • Prader-Willi Syndrome (PWS) - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top